Monday, July 1, 2013

Veracyte Gets $28M In Series C For Molecular Diagnostics Products

South San Francisco-based molecular diagnostics firm Veracyte has raised $28M in a Series C funding. The firm said the funding included GE Ventures, as well as Domain Associates, Kleiner Perkins Caufield & Byers, TPG Biotech, and Versant Ventures. Veracyte is developing molecular cytology products, which are being applied to create a gene expression test to help reduce unnecessary surgeries as part of thyroid cancer diagnosis. The firm said the funding will go towards comercial expansion of its first product. More information »